Cx-2009, A Cd166-Directed Probody Drug Conjugate (Pdc): Results From The First-In-Human Study In Patients (Pts) With Advanced Cancer Including Breast Cancer (Bc).

Valentina Boni,Howard A. Burris,Joyce F. Liu,Alexander I. Spira,Hendrik-Tobias Arkenau,Mary J. Fidler,Lee S. Rosen,Randy F. Sweis, Nataliya Volodymyrivna Uboha,Rachel E. Sanborn,Bert O'Neil,James J. Harding,Patricia LoRusso,Amy M. Weise,Javier Garcia-Corbacho,Iván Victoria,John W. Frye,Rachel Li,Mark Stroh,Funda Meric-Bernstam

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 11|浏览57

暂无评分

摘要

526Background: CX-2009 is a PROBODY drug conjugate (PDC) directed against CD166 (ALCAM) and conjugated to DM4, a potent microtubule inhibitor (MTI). CD166 is overexpressed in carcinomas but is also...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要